Amazon Vitamin C Gummy Potency Failures Demand UK Brand Due Diligence
NOW's recent testing found 48% of non-legacy Vitamin C gummy brands on Amazon failed potency, with 12 out of 25 tested products containing negligible active ingredient. This highlights critical supply chain and regulatory compliance risks for brand owners operating on major e-commerce platforms.
Illinois, United States — 20 August 2026
Natural products manufacturer NOW has released findings from its latest independent testing of Vitamin C gummy supplements sold on Amazon. Of 25 products analysed, 12 (48%) failed to meet label claims, with some showing negligible active ingredient. These failures disproportionately affected non-legacy brands, indicating a systemic issue within specific segments of the e-commerce supply chain. One product claiming 1,000 mg of Vitamin C per gummy contained less than 2 mg. NOW attributes these discrepancies to dishonest marketing, inaccurate labelling, and inadequate quality control from manufacturers.
This is not an isolated incident; NOW has repeatedly presented similar findings to Amazon and the US Food and Drug Administration (FDA) since 2017. Despite ongoing engagement, significant action to remove or address substandard products from the marketplace remains limited. The persistent availability of demonstrably under-potent products raises questions about platform accountability and the effectiveness of current regulatory oversight on third-party e-commerce channels.
The issue extends beyond Vitamin C, with NOW identifying similar potency failures across various categories including CoQ10, Ashwagandha, and N-Acetyl Cysteine (NAC) in previous testing rounds. This suggests a broader problem with quality control and compliance within specific segments of the supplement industry, particularly for brands leveraging large, open online marketplaces without stringent vetting processes.
What this means for United Kingdom
UK brand owners selling on Amazon or similar platforms must immediately enhance their quality assurance protocols, especially for products procured from non-vertically integrated suppliers. The persistent failure rate of 48% for non-legacy brands underscores the critical need for pre-market potency testing and robust supplier audits to prevent consumer safety risks and brand erosion. The UK's Food Standards Agency (FSA) and Medicines and Healthcare products Regulatory Agency (MHRA) could intensify market surveillance, potentially triggering product withdrawals and enforcement actions against non-compliant brands. Proactive compliance, including third-party testing certifications, offers a competitive advantage and mitigates future regulatory and reputational risks in a market where consumer trust is paramount.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.